Medtronic (NYSE: MDT) — Perfil da empresa, notícias e dados financeiros
Medtronic develops innovative medical technologies to improve health outcomes across diverse conditions.
Medtronic
Medtronic is a global healthcare technology company that designs, manufactures, and distributes medical devices and therapies to hospitals, physicians, and patients across more than 150 countries. The company operates through four primary segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. Its product lines encompass cardiac rhythm management systems, structural heart devices, surgical robotics, spinal implants, deep brain stimulation devices, patient monitoring solutions, and continuous glucose monitoring technologies. Headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, Minnesota, the business conducts extensive research and development to advance minimally invasive procedures, digital health ecosystems, and chronic disease management therapies.
Resumo
Operações
Produtos e/ou serviços de Medtronic
- Cardiovascular Portfolio: Development and manufacturing of cardiac rhythm management systems, transcatheter aortic valves, pacemakers, implantable cardioverter defibrillators, coronary stents, and ablation systems designed for treating vascular diseases and structural heart conditions worldwide.
- Medical Surgical Portfolio: Advanced surgical instruments, electrosurgical hardware, surgical stapling products, wound closure tools, and patient monitoring technologies supplied to hospitals and ambulatory surgery centers globally for minimally invasive and open operative procedures.
- Neuroscience Portfolio: Products and therapies for spinal, cranial, and neurological disorders, including spinal implants, deep brain stimulation systems, surgical navigation systems, and targeted drug infusion pumps used across international healthcare facilities.
- Diabetes Operating Unit: Integrated diabetes management solutions comprising automated insulin delivery systems, continuous glucose monitors, smart insulin pens, and digital software applications serving adult and pediatric patients with type 1 and type 2 diabetes.
- Robotic-Assisted Surgery: Mobile robotic-assisted surgery systems, digital ordering and procedural software, and integrated surgical ecosystem platforms designed to assist clinical teams in planning, executing, and refining complex laparoscopic and soft-tissue procedures.
- Neuromodulation and Pelvic Health: Implantable spinal cord stimulation devices, sacral neuromodulation therapies, tibial neuromodulation systems, and pelvic health implants engineered for chronic pain management, bladder control, sacral nerve conditions, and urinary urge incontinence.
equipe executiva do Medtronic
- Geoffrey Straub MarthaChairman of the Board & CEO
- Thierry PietonExecutive VP & CFO
- Michelle QuinnExecutive VP, General Counsel & Secretary
- Michael MarinaroExecutive VP and President of Medical Surgical Portfolio & Americas
- Rogerio BrancoSVP & Chief Operations and Supply Chain Officer
- Denise L. BlomquistVP, Global Controller & Chief Accounting Officer
- Laura MauriSenior VP and Chief Scientific & Medical Officer
- Ingrid GoldbergVice President & Head of Investor Relations
- Matthew R. WalterSenior Vice President of Human Resources, IT and Global Communications & Corporate Marketing
- Alex GuSenior VP & President of Greater China Region
Últimas notícias sobre a Medtronic
Medtronic receives FDA clearance for LigaSure RAS
United StatesMedtronic revenue reaches $9.76 billion amid strong performance
United StatesMedtronic caps fiscal year with revenue surge and 49th dividend increase
United StatesMedtronic to acquire pain-management device maker SPR Therapeutics for $650M
United StatesMedtronic to acquire Scientia Vascular for $550M to bolster stroke care
United StatesMedtronic posts Q3 FY26 revenue of $9.017B, up 8.7%
United States
Histórico de dividendos
Dividendos por ação pagos pela Medtronic , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2027(até o momento) | — | — | — | $1.4400 |
| FY2026 | — | — | — | $2.8400 |
| FY2025 | — | — | — | $2.8000 |
| FY2024 | — | — | — | $2.7600 |
| FY2023 | — | — | — | $2.7200 |
Principais indicadores financeiros
Resultados divulgados pela Medtronic , em USD.
- Cap. de mercado
- 120,2 bi
- Receita (TTM)
- 37,5 bi
- P/L
- 23.1
- LPA (diluído, TTM)
- 4.1
- Dividend yield
- 3.0%
- Margem de lucro
- 13.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 36,4 bi | 6,5 bi | 4,8 bi | |
| 33,5 bi | 6 bi | 4,7 bi | |
| 32,4 bi | 5,1 bi | 3,7 bi | |
| 31,2 bi | 5,5 bi | 3,8 bi |